None listed
Conditions
Interventions
Intervention1: Tapentadol Nasal Spray: Two sprays per dose 22.5mg of drug dispensed per spray so total 45mg of drug per dose three times a day for three days
Intervention2: Tapentadol Hydrochloride or
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who consent to be part of the study. 2.Patients ranging from the age of 18-35 years. 3.Patients in ASA 1 category 4.Patients with mesioangular Impacted 3rd molars with class 2 position B (Pell and Gregory classification) indicated for trans-alveolar extraction under local anesthesia.
Exclusion criteria
Exclusion criteria: 1.Patients who do not consent to be part of the study 2.Patients with significant medical comorbidities eg. Diabetes, Hypertension, thyroid discrepancies, bronchial asthma, and other medical concerns 3.Patient allergic to active drug prescribed - Tapendtadol 4.Patients with underlying nasal pathologies like allergic rhinitis, nasal polyps, and deviated septum. 5.Pregnant women or lactating mothers 6.Patients taking selective serotonin reuptake inhibitors (SSRIs) 7.Patients taking opioid like medications eg. Pentazocine, nalbuphimine 8.Acute alcoholism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tapentadol nasal spray is a superior analgesic than oral tapetatadol of zerodol pTimepoint: Visual Analog Pain Scale to be checked at 6hr post operatively 1st day post operatively and 3rd day post opeartively | — |
Secondary
| Measure | Time frame |
|---|---|
| nilTimepoint: nil | — |
Countries
India
Contacts
Public ContactDr Poorva Kulkarni
Meenakshi Academy of Higher education
Outcome results
None listed